Altered microbiome of chronic pelvic pain
US-2015284781-A1 · Oct 8, 2015 · US
Altered microbiome of chronic pelvic pain
US10316368B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10316368-B2 |
| Application number | US-201715729249-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 10, 2017 |
| Priority date | Apr 2, 2014 |
| Publication date | Jun 11, 2019 |
| Grant date | Jun 11, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are kits, compositions, and methods for diagnosing and treating interstitial cystitis (IC) and/or interstitial cystitis/bladder pain syndrome (IC/BPS) based on finding lower levels of certain bacteria in a subject's stool sample (e.g., O. splanchnicus, F. prausnitzii, C. aerofaciens, E. sinensis, L. longoviformis, and R. intestinalis). In certain embodiments, then present invention provides probiotic formulations containing live bacteria (e.g., from O. splanchnicus, F. prausnitzii, C. aerofaciens, E. sinensis, L. longoviformis, and R. intestinalis).
First claim
Opening claim text (preview).
We claim: 1. A probiotic formulation comprising at least three species of live bacteria from the genera of bacteria selected from the group consisting of: Odoribacter, Faecalibacterium, Collinsella, Eggerthella, Lactonifactor , and Roseburia , wherein at least two species are selected from the group consisting of: Odoribacter splanchnicus, Collinsella aerofaciens, Eggerthella sinensis, Lactonifactor longoviformis , and Roseburia intestinalis. 2. The probiotic formulation of claim 1 , comprising at least three species selected from the group consisting of: Odoribacter splanchnicus, Faecalibacterium prausnitzii, Collinsella aerofaciens, Eggerthella sinensis, Lactonifactor longoviformis , and Roseburia intestinalis. 3. The probiotic formulation of claim 2 , comprising at least four species selected from the group consisting of: Odoribacter splanchnicus, Faecalibacterium prausnitzii, Collinsella aerofaciens, Eggerthella sinensis, Lactonifactor longoviformis , and Roseburia intestinalis. 4. The probiotic formulation of claim 3 , comprising at least five species selected from the group consisting of: Odoribacter splanchnicus, Faecalibacterium prausnitzii, Collinsella aerofaciens, Eggerthella sinensis, Lactonifactor longoviformis , and Roseburia intestinalis. 5. The probiotic formulation of claim 4 , comprising Odoribacter splanchnicus, Faecalibacterium prausnitzii, Collinsella hella sinensis, Lactonifactor longoviformis , and Roseburia intestinalis. 6. The probiotic formulation of claim 1 , further comprising a capsule formulated for human consumption with the live bacteria contained therein. 7. A kit comprising the probiotic formulation of claim 1 , and a therapeutic agent for the treatment of interstitial cystitis.
Assignees
Inventors
Classifications
for diseases caused by alterations of genetic material · CPC title
Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06) · CPC title
- C12Q1/689Primary
for bacteria · CPC title
Probiotics · CPC title
Bacteria (therapeutic use of a bacterial protein A61K38/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10316368B2 cover?
- Provided herein are kits, compositions, and methods for diagnosing and treating interstitial cystitis (IC) and/or interstitial cystitis/bladder pain syndrome (IC/BPS) based on finding lower levels of certain bacteria in a subject's stool sample (e.g., O. splanchnicus, F. prausnitzii, C. aerofaciens, E. sinensis, L. longoviformis, and R. intestinalis). In certain embodiments, then present invent…
- Who is the assignee on this patent?
- Univ Northwestern, Univ Illinois, The Board Of Trustees Of The Univ Of Illinoi
- What technology area does this patent fall under?
- Primary CPC classification C12Q1/689. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).